Wolfgang Hiddemann

47.3k total citations · 7 hit papers
644 papers, 27.2k citations indexed

About

Wolfgang Hiddemann is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Wolfgang Hiddemann has authored 644 papers receiving a total of 27.2k indexed citations (citations by other indexed papers that have themselves been cited), including 261 papers in Hematology, 256 papers in Pathology and Forensic Medicine and 209 papers in Oncology. Recurrent topics in Wolfgang Hiddemann's work include Acute Myeloid Leukemia Research (241 papers), Lymphoma Diagnosis and Treatment (238 papers) and Chronic Lymphocytic Leukemia Research (137 papers). Wolfgang Hiddemann is often cited by papers focused on Acute Myeloid Leukemia Research (241 papers), Lymphoma Diagnosis and Treatment (238 papers) and Chronic Lymphocytic Leukemia Research (137 papers). Wolfgang Hiddemann collaborates with scholars based in Germany, United States and Switzerland. Wolfgang Hiddemann's co-authors include Claudia Schoch, Susanne Schnittger, Torsten Haferlach, Wolfgang Kern, Michael Unterhalt, Bernhard Wörmann, Thomas Büchner, Martin Dreyling, Karsten Spiekermann and Gerhard Behre and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wolfgang Hiddemann

629 papers receiving 26.6k citations

Hit Papers

Report of an Internationa... 1984 2026 1998 2012 1999 2002 2001 2007 1984 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
    1999 2.8k citations Anton Hagenbeek, Wolfgang Hiddemann et al. Journal of Clinical Oncology profile →
  2. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    2002 746 citations Susanne Schnittger, Claudia Schoch et al. Blood profile →
  3. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
    2001 681 citations Susanne Schnittger, Wolfgang Hiddemann et al. profile →
  4. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    2007 621 citations Eva Hoster, Martin Dreyling et al. Blood profile →
  5. Convention on nomenclature for DNA cytometry
    1984 538 citations Wolfgang Hiddemann et al. profile →
  6. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
    2010 486 citations Rolf D. Issels, Clemens‐Martin Wendtner et al. profile →
  7. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
    2017 461 citations Robert Marcus, Andrew Davies et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wolfgang Hiddemann Germany 79 11.0k 9.8k 9.3k 8.1k 6.9k 644 27.2k
David C. Linch United Kingdom 74 8.9k 0.8× 6.6k 0.7× 7.0k 0.7× 4.8k 0.6× 4.9k 0.7× 358 20.9k
John F. Seymour Australia 74 7.9k 0.7× 9.8k 1.0× 6.8k 0.7× 5.1k 0.6× 10.7k 1.6× 561 23.8k
Francis J. Giles United States 105 20.4k 1.9× 6.3k 0.6× 9.3k 1.0× 15.0k 1.9× 15.8k 2.3× 786 41.9k
Bruce D. Cheson United States 69 6.4k 0.6× 17.1k 1.7× 10.6k 1.1× 5.0k 0.6× 11.0k 1.6× 362 29.9k
Deborah A. Thomas United States 80 12.3k 1.1× 5.5k 0.6× 4.9k 0.5× 6.3k 0.8× 10.2k 1.5× 451 23.2k
Alessandro Rambaldi Italy 83 9.6k 0.9× 4.7k 0.5× 5.6k 0.6× 8.1k 1.0× 8.5k 1.2× 661 24.3k
Thomas E. Witzig United States 101 9.6k 0.9× 14.1k 1.4× 13.5k 1.5× 11.2k 1.4× 8.6k 1.2× 778 34.1k
William G. Wierda United States 88 11.0k 1.0× 13.0k 1.3× 8.1k 0.9× 8.5k 1.1× 18.2k 2.6× 829 31.7k
L. Jeffrey Medeiros United States 91 7.7k 0.7× 18.8k 1.9× 14.3k 1.5× 9.2k 1.1× 10.3k 1.5× 1.3k 40.1k
Susan O’Brien United States 100 21.3k 1.9× 8.4k 0.9× 7.4k 0.8× 8.3k 1.0× 17.3k 2.5× 840 36.5k

Countries citing papers authored by Wolfgang Hiddemann

Since Specialization
Citations

This map shows the geographic impact of Wolfgang Hiddemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Hiddemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Hiddemann more than expected).

Fields of papers citing papers by Wolfgang Hiddemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Hiddemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Hiddemann. The network helps show where Wolfgang Hiddemann may publish in the future.

Co-authorship network of co-authors of Wolfgang Hiddemann

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Hiddemann. A scholar is included among the top collaborators of Wolfgang Hiddemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Hiddemann. Wolfgang Hiddemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919. 27 indexed citations
2.
Rausch, Christian, Maja Rothenberg‐Thurley, Annika Dufour, et al.. (2023). Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 37(6). 1234–1244. 45 indexed citations
3.
Kostakoğlu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2023). A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. SHILAP Revista de lepidopterología. 4(4). 1042–1051. 1 indexed citations
4.
Alcazer, Vincent, Paola Bonaventura, Laurie Tonon, et al.. (2022). HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. American Journal of Hematology. 97(9). 1200–1214. 15 indexed citations
5.
Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745. 3 indexed citations
6.
Klánová, Magdalena, Mikkel Z. Oestergaard, Marek Trněný, et al.. (2019). Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clinical Cancer Research. 25(15). 4634–4643. 54 indexed citations
7.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404. 144 indexed citations
8.
9.
Reindl, Carola, Hilmar Quentmeier, Konstantin Petropoulos, et al.. (2009). CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes. Clinical Cancer Research. 15(7). 2238–2247. 89 indexed citations
10.
Dufour, Annika, Friederike Schneider, Klaus H. Metzeler, et al.. (2009). Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. Journal of Clinical Oncology. 28(4). 570–577. 189 indexed citations
11.
Schneider, Friederike, Eva Hoster, Michael Unterhalt, et al.. (2009). NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood. 113(21). 5250–5253. 48 indexed citations
12.
Büchner, Thomas, Wolfgang E. Berdel, Claudia Haferlach, et al.. (2008). Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology. 27(1). 61–69. 232 indexed citations
13.
14.
Braess, Jan, et al.. (2005). Modeling the Pharmacodynamics of Highly Schedule-Dependent Agents: Exemplified by Cytarabine-Based Regimens in Acute Myeloid Leukemia. Clinical Cancer Research. 11(20). 7415–7425. 7 indexed citations
15.
Issels, Rolf D., S. Abdel-Rahman, Clemens‐Martin Wendtner, et al.. (2001). Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults. European Journal of Cancer. 37(13). 1599–1608. 73 indexed citations
16.
Hiddemann, Wolfgang, et al.. (1998). Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities. Leukemia Research. 22. S23–S26. 7 indexed citations
17.
Wulf, Gerald, Frank Strutz, M. Hüfner, et al.. (1996). Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Annals of Hematology. 73(3). 139–141. 27 indexed citations
18.
Harstrick, A., Carsten Bokemeyer, Andreas Mügge, et al.. (1993). Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer. 72(7). 2242–2247. 89 indexed citations
19.
Eiff, M. von, M. Essink, N. Roos, et al.. (1990). Hepatosplenic candidiasis, a late manifestation of Candida septicaemia in neutropenic patients with haematologic malignancies. Annals of Hematology. 60(4). 242–248. 41 indexed citations
20.
Urbanitz, D., et al.. (1981). Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL) treatment report on 60 patients. Annals of Hematology. 43(2). 129–133. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David C. Linch Breakdown of academic impact, for papers by John F. Seymour Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Bruce D. Cheson Breakdown of academic impact, for papers by Deborah A. Thomas Breakdown of academic impact, for papers by Alessandro Rambaldi Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by William G. Wierda Breakdown of academic impact, for papers by L. Jeffrey Medeiros Breakdown of academic impact, for papers by Susan O’Brien
Rankless by CCL
2026